Baxter International Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Baxter International Inc (BAX). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Medical Products and Therapies | – | $4.82B 40.2% | $4.82B 48.7% · -0.1% | $5.01B 48.8% · +4.1% | $5.21B 49.3% · +3.9% |
| Healthcare Systems and Technologies | – | $212.0M 1.8% | $2.94B 29.7% · +1,286.3% | $3.01B 29.3% · +2.5% | $2.95B 27.9% · -2.1% |
| Pharmaceuticals | – | $2.29B 19.1% | $2.13B 21.5% · -7.2% | $2.25B 21.9% · +5.8% | $2.41B 22.8% · +7.2% |
| Americas | $6.32B 54.2% | – | – | – | – |
| EMEA | $2.88B 24.6% | – | – | – | – |
| APAC | $2.48B 21.2% | – | – | – | – |
| Hillrom | $0 0.0% | – | – | – | – |
| Kidney Care | – | $4.68B 39.0% | – | – | – |
| Other | – | – | – | – | – |
| Reportable Segment | – | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Medical Products and Therapies | – | $955.0M 19.8% | $962.0M 20.0% | $972.0M 19.4% | $950.0M 18.2% |
| Healthcare Systems and Technologies | – | $60.0M 28.3% | $494.0M 16.8% | $483.0M 16.0% | $468.0M 15.9% |
| Pharmaceuticals | – | $523.0M 22.8% | $391.0M 18.4% | $401.0M 17.8% | $313.0M 13.0% |
| Americas | – | – | – | – | – |
| EMEA | – | – | – | – | – |
| APAC | – | – | – | – | – |
| Hillrom | – | – | – | – | – |
| Kidney Care | – | $488.0M 10.4% | – | – | – |
| Other | – | $59.0M | – | – | – |
| Reportable Segment | – | – | $1.85B | $1.86B | $1.73B |
Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.
Revenue by product line
| Segment | 2020 | 2021 | 2022 |
|---|---|---|---|
| Renal Care | $3.76B 32.2% | $3.90B 30.5% · +3.8% | $3.75B 24.8% · -3.9% |
| Medication Delivery | $2.69B 23.1% | $2.88B 22.5% · +7.0% | $2.89B 19.1% · +0.2% |
| Pharmaceuticals | $2.10B 18.0% | $2.29B 17.9% · +9.2% | $2.13B 14.1% · -7.2% |
| Patient support systems | $0 0.0% | $115.0M 0.9% | $1.49B 9.8% · +1,193.0% |
| Front line care | $0 0.0% | $70.0M 0.5% | $1.15B 7.6% · +1,540.0% |
| Advanced Surgery | $886.0M 7.6% | $977.0M 7.6% · +10.3% | $1.00B 6.6% · +2.1% |
| Clinical Nutrition | $910.0M 7.8% | $964.0M 7.5% · +5.9% | $931.0M 6.2% · -3.4% |
| Acute Therapies | $740.0M 6.3% | $782.0M 6.1% · +5.7% | $701.0M 4.6% · -10.4% |
| BioPharma Solutions | $486.0M 4.2% | $669.0M 5.2% · +37.7% | $644.0M 4.3% · -3.7% |
| Surgical solutions | $0 0.0% | $27.0M 0.2% | $304.0M 2.0% · +1,025.9% |
| Other | $105.0M 0.9% | $109.0M 0.9% · +3.8% | $140.0M 0.9% · +28.4% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 10, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.